Positive interim data from long-term open-label Phase III safety study of tapinarof cream in plaque psoriasis

In the ongoing PSOARING 3 study, 57.3% of patients had a PGA response of 0 (clear) or 1 (almost clear) plus a 2-grade improvement from baseline at any point in the study and 39.2% achieved complete disease clearance. A total of 5.8% discontinued the cream due to adverse events.

Source:

Biospace Inc.